ArticleThe Biochemical journal1980
The ATP4- receptor of rat mast cells.
Article in The Biochemical journal, 1980. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 224 citations in OpenAlex.
- Role of Oxysterols in Ocular Degeneration Mechanisms and Involvement of P2X7 Receptor.Advances in experimental medicine and biology · 2024Article
- Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer.Purinergic signalling · 2021Review
- P2X7 is a cytotoxic receptor….maybe not: implications for cancer.Purinergic signalling · 2021Review
- Review
- Involvement of P2 receptors in hematopoiesis and hematopoietic disorders, and as pharmacological targets.Purinergic signalling · 2020Review
- Mast Cells and Their Progenitors in Allergic Asthma.Frontiers in immunology · 2019Review
- Extracellular ATP and P2 purinergic signalling in the tumour microenvironment.Nature reviews. Cancer · 2018Review
- Non-nucleotide Agonists Triggering P2X7 Receptor Activation and Pore Formation.Frontiers in pharmacology · 2018Review
- P2RX7 Purinoceptor as a Therapeutic Target-The Second Coming?Frontiers in chemistry · 2018Review
- The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?Frontiers in pharmacology · 2018Review
- Purinergic signaling in infection and autoimmune disease.Biomedical journal · 2016Article
- Purinergic signalling in autoimmunity: A role for the P2X7R in systemic lupus erythematosus?Biomedical journal · 2016Review
- P2X ion channel receptors and inflammation.Purinergic signalling · 2016Review
- A new role for P2X4 receptors as modulators of lung surfactant secretion.Frontiers in cellular neuroscience · 2013Review
- Is pannexin the pore associated with the P2X7 receptor?Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
- P2 receptor-mediated signaling in mast cell biology.Purinergic signalling · 2010Article
- Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells.British journal of pharmacology · 2009Article
- P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways.Purinergic signalling · 2009Article
- Inhibition of P2X(7) receptors by divalent cations: old action and new insight.European biophysics journal : EBJ · 2009Review
- P2X(7) receptor: Death or life?Purinergic signalling · 2005Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concentration-dependence on exogenous ATP of activation and inhibition of mast-cell histamine secretion, phosphatidylinositol labelling and leakage of metabolites shows that all these functions are regulated by the free acid ATP4-. Maximal histamine secretion and phosphatidylinositol labelling occur with ATP4- at approx. 2 microM, but higher concentrations, which cause inhibition of secretion and phosphatidylinositol labelling, are required to maximize leakage of 32P-labelled metabolites. Both enhancement and inhibition of phosphatidylinositol labelling (due to low and high concentrations of ATP4- respectively) are rapid in onset; histamine secretion is characterized by a delay, especially at low concentrations of ATP4- (approx. 1 microM). Phosphatidylinositol labelling and histamine secretion are dependent on extracellular Ca2+. Metabolite leakage due to the presence of exogenous ATP4- is slow and does not require Ca2+. Of 18 analogues of ATP that were tested, only four were agonists for secretion, and only these four permitted leakage of 32P-labelled metabolites. It is argued that activation and inhibition of histamine secretion, phosphatidylinositol labelling and metabolite leakage are all initiated by ATP4- acting at the same receptor. For mast cells stimulated with ATP4- enhancement of phosphatidylinositol metabolism is not sufficient by itself to cause Ca2+-dependent secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.